Multiple myeloma (MM) is an incurable haematological malignancy, but patient survival outcomes have been lately improved by recent advances in treatment. Despite this innovation, however, MM patients ...

Tumour Treating Fields (TTFields) present a completely different approach to cancer therapy, involving alternating electric ...

The FDA is moving at breakneck speed to roll out a generative artificial intelligence (AI) tool for speeding up regulatory ...

The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

Shareholders in the Nasdaq-listed German company, which is backed by billionaire investor and PayPal co-founder Peter Thiel, ...

Meanwhile, BioNTech itself bought into the category with its takeover of BNT327's developer Biotheus unit last year for what ...

According to AZ, SERENA-6 is also the first pivotal trial to show the value of measuring circulating tumour DNA (ctDNA) to ...

23andMe has said it wants to allow new bids by both parties with a deadline of 12th June, according to a Financial Times ...

Hudson has previously said he was looking for M&A deals this year to shore up its already-strong position in immunology, ...

As ASCO 2025 commenced in Chicago on Friday 30th May, pharmaphorum headed over to the Windy City’s Willis Tower for Johnson & ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

Libtayo (cemiplimab) was cleared in 2018 for treating advanced CSCC in patients who are not candidates for curative surgery ...